CIBC Bancorp USA Inc. Acquires Shares of 351,753 Novo Nordisk A/S $NVO

CIBC Bancorp USA Inc. bought a new position in Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 351,753 shares of the company’s stock, valued at approximately $19,519,000.

A number of other large investors have also recently modified their holdings of the stock. Beacon Financial Group increased its position in shares of Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after buying an additional 178 shares during the period. Kavar Capital Partners Group LLC lifted its holdings in Novo Nordisk A/S by 0.6% in the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after buying an additional 200 shares during the period. SeaBridge Investment Advisors LLC lifted its holdings in Novo Nordisk A/S by 5.7% in the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock worth $207,000 after buying an additional 200 shares during the period. Joel Isaacson & Co. LLC boosted its position in Novo Nordisk A/S by 1.0% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 200 shares in the last quarter. Finally, Revolve Wealth Partners LLC boosted its position in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research report on Tuesday, March 3rd. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday. Finally, Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research report on Wednesday. They set an “outperform” rating and a $175.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (Wegovy HD), showing ~20.7% mean weight loss in the STEP UP trial — approval moved through an accelerated priority pathway and Novo expects a U.S. launch in April 2026, giving the company a stronger product to regain share vs. rivals. FDA approves Novo Nordisk’s new Wegovy® HD injection
• Positive Sentiment: Sell‑side catalyst: Sanford C. Bernstein initiated coverage with an “outperform” and a high $175 PT, signaling potential upside and providing a supporting narrative for long‑term investors.
• Positive Sentiment: Real‑world retention tailwind — a study flagged that stopping GLP‑1s raises cardiovascular risks, which supports chronic use and could bolster prescription persistence for Wegovy and related products. Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Positive Sentiment: Novo is expanding access efforts in Japan (self‑pay pathways), which could add incremental revenue in a large underpenetrated market. Novo Nordisk Seeking to Expand Weight-Loss Drugs Access in Japan
• Positive Sentiment: Pipeline diversification: positive Phase‑2 data for investigational obesity candidate UBT251 (triple agonist) adds another growth option beyond semaglutide. Novo Nordisk Obesity Drug Data Sparks Questions On Valuation And Momentum
• Negative Sentiment: Patent expiration on semaglutide in India this week opens the door to low‑cost generics and potential share/pricing erosion in a large market — a clear near‑term revenue risk in that geography. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
• Negative Sentiment: Competitive pressure intensifies — Eli Lilly confirmed superior weight‑loss with next‑gen candidate retatrutide, and Roche is re‑entering obesity, raising the risk of share loss and pricing pressure over time. Eli Lilly Confirms ‘Superior Weight Loss’ Of Its Next-Generation Obesity Drug

Novo Nordisk A/S Price Performance

NVO stock opened at $37.05 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a 50 day moving average price of $48.67 and a 200-day moving average price of $51.29. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $81.44. The firm has a market capitalization of $165.44 billion, a price-to-earnings ratio of 10.68 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.